{"nctId":"NCT01635764","briefTitle":"Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa","startDateStruct":{"date":"2012-04","type":"ACTUAL"},"conditions":["Hidradenitis Suppurativa"],"count":508,"armGroups":[{"label":"Adalimumab Every Week","type":"EXPERIMENTAL","interventionNames":["Biological: adalimumab"]}],"interventions":[{"name":"adalimumab","otherNames":["Humira"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who previously participated in a prior Phase 3 AbbVie hidradenitis suppurativa (HS) study (M11-313 or M11-810) and:\n\n  1. Completed the study; or\n  2. Experienced a loss of response (LOR); or\n  3. Experienced worsening or absence of improvement\n\n     Exclusion Criteria:\n* Prior treatment with any other anti-tumour necrosis factor (anti-TNF) therapy (e.g., infliximab, etanercept), or participation in an adalimumab trial other than a prior Phase 3 AbbVie HS study.\n* Subject received any oral antibiotic treatment for HS within 28 days prior to the Baseline visit, except for antibiotics permitted in a prior Phase 3 AbbVie HS study.\n* Subject received prescription topical therapies for the treatment of HS within 14 days prior to the Baseline visit of Study M12-555.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit","description":"Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"39.8","spread":null},{"groupId":"OG002","value":"34.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"41.1","spread":null},{"groupId":"OG002","value":"40.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"48.9","spread":null},{"groupId":"OG002","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"51.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"56.7","spread":null},{"groupId":"OG002","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"45.6","spread":null},{"groupId":"OG002","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"47.8","spread":null},{"groupId":"OG002","value":"42.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"52.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"58.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"57.8","spread":null},{"groupId":"OG002","value":"58.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.1","spread":null},{"groupId":"OG001","value":"61.1","spread":null},{"groupId":"OG002","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"56.7","spread":null},{"groupId":"OG002","value":"55.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"56.7","spread":null},{"groupId":"OG002","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"52.2","spread":null},{"groupId":"OG002","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null},{"groupId":"OG001","value":"52.2","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"52.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"52.2","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null},{"groupId":"OG001","value":"53.3","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit","description":"Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit","description":"Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit","description":"The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit","description":"The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":null},{"groupId":"OG001","value":"22.8","spread":null},{"groupId":"OG002","value":"21.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":null},{"groupId":"OG001","value":"34.8","spread":null},{"groupId":"OG002","value":"44.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"42.4","spread":null},{"groupId":"OG002","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"44.6","spread":null},{"groupId":"OG002","value":"45.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"41.3","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"46.7","spread":null},{"groupId":"OG002","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null},{"groupId":"OG001","value":"45.7","spread":null},{"groupId":"OG002","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"42.4","spread":null},{"groupId":"OG002","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"43.5","spread":null},{"groupId":"OG002","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"43.5","spread":null},{"groupId":"OG002","value":"54.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"44.6","spread":null},{"groupId":"OG002","value":"50.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"40.2","spread":null},{"groupId":"OG002","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"40.2","spread":null},{"groupId":"OG002","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null},{"groupId":"OG001","value":"37.0","spread":null},{"groupId":"OG002","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"37.0","spread":null},{"groupId":"OG002","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"41.3","spread":null},{"groupId":"OG002","value":"52.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"39.1","spread":null},{"groupId":"OG002","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"35.9","spread":null},{"groupId":"OG002","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"35.9","spread":null},{"groupId":"OG002","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1","spread":null},{"groupId":"OG001","value":"35.9","spread":null},{"groupId":"OG002","value":"51.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit","description":"The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population","description":"The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.0","spread":"25.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.0","spread":"31.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.8","spread":"35.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.9","spread":"48.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.6","spread":"54.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.1","spread":"73.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.6","spread":"74.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.6","spread":"93.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.2","spread":"115.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.9","spread":"119.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.2","spread":"122.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.8","spread":"123.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.2","spread":"126.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.2","spread":"124.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.4","spread":"127.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.5","spread":"128.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.4","spread":"129.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.7","spread":"130.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.5","spread":"130.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.8","spread":"129.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.9","spread":"130.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.4","spread":"130.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.4","spread":"130.94"}]}]}]},{"type":"PRIMARY","title":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations","description":"The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.1","spread":"56.94"},{"groupId":"OG001","value":"-10.5","spread":"56.74"},{"groupId":"OG002","value":"0.2","spread":"51.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.2","spread":"48.99"},{"groupId":"OG001","value":"-18.8","spread":"56.52"},{"groupId":"OG002","value":"-16.2","spread":"56.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.9","spread":"47.42"},{"groupId":"OG001","value":"-21.2","spread":"63.26"},{"groupId":"OG002","value":"-24.8","spread":"51.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.8","spread":"55.71"},{"groupId":"OG001","value":"-25.5","spread":"57.92"},{"groupId":"OG002","value":"-26.2","spread":"54.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.9","spread":"47.92"},{"groupId":"OG001","value":"-26.2","spread":"60.59"},{"groupId":"OG002","value":"-32.3","spread":"48.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.1","spread":"47.39"},{"groupId":"OG001","value":"-24.1","spread":"61.52"},{"groupId":"OG002","value":"-33.5","spread":"50.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.1","spread":"46.07"},{"groupId":"OG001","value":"-24.7","spread":"63.81"},{"groupId":"OG002","value":"-33.6","spread":"57.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.5","spread":"47.94"},{"groupId":"OG001","value":"-24.8","spread":"63.21"},{"groupId":"OG002","value":"-30.2","spread":"64.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.8","spread":"50.17"},{"groupId":"OG001","value":"-22.6","spread":"65.06"},{"groupId":"OG002","value":"-31.7","spread":"66.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.4","spread":"55.22"},{"groupId":"OG001","value":"-20.1","spread":"64.52"},{"groupId":"OG002","value":"-31.8","spread":"65.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.6","spread":"51.33"},{"groupId":"OG001","value":"-20.0","spread":"66.02"},{"groupId":"OG002","value":"-29.5","spread":"65.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.0","spread":"49.42"},{"groupId":"OG001","value":"-18.3","spread":"65.14"},{"groupId":"OG002","value":"-29.0","spread":"68.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.0","spread":"54.41"},{"groupId":"OG001","value":"-18.3","spread":"66.88"},{"groupId":"OG002","value":"-28.4","spread":"71.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.8","spread":"60.85"},{"groupId":"OG001","value":"-16.2","spread":"66.82"},{"groupId":"OG002","value":"-28.3","spread":"70.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.1","spread":"53.01"},{"groupId":"OG001","value":"-16.7","spread":"66.87"},{"groupId":"OG002","value":"-28.8","spread":"69.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.1","spread":"53.94"},{"groupId":"OG001","value":"-16.6","spread":"67.30"},{"groupId":"OG002","value":"-28.6","spread":"70.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.7","spread":"53.95"},{"groupId":"OG001","value":"-15.7","spread":"67.09"},{"groupId":"OG002","value":"-28.0","spread":"69.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.6","spread":"53.72"},{"groupId":"OG001","value":"-15.5","spread":"67.40"},{"groupId":"OG002","value":"-28.7","spread":"69.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.6","spread":"53.64"},{"groupId":"OG001","value":"-15.4","spread":"67.39"},{"groupId":"OG002","value":"-28.7","spread":"69.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.6","spread":"53.64"},{"groupId":"OG001","value":"-15.4","spread":"67.39"},{"groupId":"OG002","value":"-28.7","spread":"69.81"}]}]}]},{"type":"PRIMARY","title":"Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population","description":"The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.0","spread":"38.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.2","spread":"48.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.0","spread":"53.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.5","spread":"57.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.1","spread":"61.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.2","spread":"60.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.5","spread":"67.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.8","spread":"64.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.5","spread":"70.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.0","spread":"74.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.9","spread":"75.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.4","spread":"78.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.4","spread":"76.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.0","spread":"76.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.1","spread":"75.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.8","spread":"75.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.8","spread":"75.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.9","spread":"75.96"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3","description":"The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \"last 24 hours.\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3","description":"The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \"last 24 hours.\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"21.9","spread":null},{"groupId":"OG002","value":"22.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null},{"groupId":"OG001","value":"43.1","spread":null},{"groupId":"OG002","value":"44.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null},{"groupId":"OG001","value":"47.6","spread":null},{"groupId":"OG002","value":"51.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"54.0","spread":null},{"groupId":"OG002","value":"51.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"50.8","spread":null},{"groupId":"OG002","value":"55.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"47.6","spread":null},{"groupId":"OG002","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2","spread":null},{"groupId":"OG001","value":"47.6","spread":null},{"groupId":"OG002","value":"55.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"50.8","spread":null},{"groupId":"OG002","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"50.8","spread":null},{"groupId":"OG002","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"46.0","spread":null},{"groupId":"OG002","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"50.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"47.6","spread":null},{"groupId":"OG002","value":"45.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"47.6","spread":null},{"groupId":"OG002","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"50.8","spread":null},{"groupId":"OG002","value":"47.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","spread":null},{"groupId":"OG001","value":"46.0","spread":null},{"groupId":"OG002","value":"49.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"49.2","spread":null},{"groupId":"OG002","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"49.2","spread":null},{"groupId":"OG002","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"49.2","spread":null},{"groupId":"OG002","value":"48.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3","description":"The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \"last 24 hours.\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3","description":"The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \"last 24 hours.\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3","description":"The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \"last 24 hours.\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":null},{"groupId":"OG001","value":"37.7","spread":null},{"groupId":"OG002","value":"31.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":null},{"groupId":"OG001","value":"46.8","spread":null},{"groupId":"OG002","value":"61.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null},{"groupId":"OG001","value":"55.8","spread":null},{"groupId":"OG002","value":"61.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"59.6","spread":null},{"groupId":"OG002","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"59.6","spread":null},{"groupId":"OG002","value":"63.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"53.8","spread":null},{"groupId":"OG002","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"48.1","spread":null},{"groupId":"OG002","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"51.9","spread":null},{"groupId":"OG002","value":"58.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"53.8","spread":null},{"groupId":"OG002","value":"55.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"59.6","spread":null},{"groupId":"OG002","value":"55.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"48.1","spread":null},{"groupId":"OG002","value":"52.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null},{"groupId":"OG001","value":"57.7","spread":null},{"groupId":"OG002","value":"57.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"44.2","spread":null},{"groupId":"OG002","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"48.1","spread":null},{"groupId":"OG002","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"46.2","spread":null},{"groupId":"OG002","value":"55.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"48.1","spread":null},{"groupId":"OG002","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"48.1","spread":null},{"groupId":"OG002","value":"54.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"48.1","spread":null},{"groupId":"OG002","value":"54.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3","description":"The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the \"last 24 hours.\" The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":99,"n":508},"commonTop":["HIDRADENITIS","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","HEADACHE","INFLUENZA"]}}}